Davita Inc. (DVA)
Health Care · Health Care Services · US stock · S&P 500 component
$187.31
▼ -1.85 (0.98%)
Fair valueData under review
$505
$253fair band $354–$657$758
Day's range
$186.54 – $189.91
52-week range
$101.00 – $247.49
Red flags⚠ Negative equity
About Davita Inc.
DaVita provides kidney care services, and is best known for operating a large network of outpatient dialysis centers in the United States and in several other countries. It treats patients with chronic kidney failure and offers related services such as home dialysis and integrated care. Revenue comes mainly from government programs like Medicare and from commercial insurers, so reimbursement rates matter greatly.
Revenue at Davita Inc. was $14.0 billion across the last twelve months. Across three years, sales expanded by 5.5% a year. Operating profit was 15.2% of revenue. It earned a return on invested capital of 18%. Debt after cash comes to 3.6 times EBITDA. There is no dividend. On the site's X-Ray Score, it rates 66 out of 100. Net debt to EBITDA compares borrowings, less cash, with annual operating earnings before interest, tax, depreciation and amortization.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $101.00 – $247.49Volume 505,300Daily, split-adjusted
Vitals
Market cap$12.4B
52-week range$101.00 – $247.49
Volume (last day)505,300
P/E (TTM)11.3
EBIT / EV yield9.4%
Free-cash-flow yield13.0%
Dividend yieldNo dividend
Revenue (TTM)$14.0B
Net income (TTM)$1.2B
Operating margin15.2%
Return on capital18.1%
Debt incl. leases$10.8B
Cash & securities$689M
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$505model spread $475 – $538
Data under review
+0.0% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is Medium, so the safety margin is 30%.
Price $187
Undervalued < $354Fair $354 – $657Overvalued > $657
10-year DCF (market-scaled)
$418
Peer multiples
$532
Earnings power floor (not blended)
$143
Fundamentals-adjusted multiple
$565
Growth the price implies
-0.2%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Read the lenses below
The price sits inside our fair-value band. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Strong
95/100
Cheap against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield9.4%
Free-cash-flow yield13.0%
Fair value vs price2.7×
Growth
Fair
61/100
Growing at a typical pace for its sector.
See the numbers →
Revenue growth (3y)5.5%
EPS growth (3y)18.9%
Growth consistency100%
Profitability
Fair
62/100
Returns on capital are typical for its sector.
See the numbers →
Return on invested capital18.1%
Operating margin15.2%
Financial health
Weak
42/100
Balance sheet is more stretched than most peers.
See the numbers →
Piotroski F-Score6 / 9
Net debt / EBITDA3.6×
Interest coverNo interest cost
Dividends
None
–/100
Pays no dividend.
See the numbers →
Quarterly results: last 6 quarters
+5.0%
Mar '25
+6.1%
Jun '25
+4.8%
Sep '25
+9.9%
Dec '25
+6.0%
Mar '26
+5.2%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $3.6B, diluted EPS $4.02.
Compare with peers
CI Cigna Group66 DGX Quest Diagnostics Inc57 CVS CVS HEALTH Corp52 LH Labcorp Holdings Inc.46Other Health Care Services companies by X-Ray Score.
Fundamentals checklist
● 7 Good · ● 6 Average · ● 2 BadCash quality
Earnings backed by cashGood
Free-cash-flow yieldGood
Risk models
Altman Z''Bad
Piotroski F-ScoreAverage
Growth
EPS growth (3y)Good
Free-cash-flow growth (3y)Average
Revenue growth (3y)Average
Growth consistencyGood
Balance sheet
Current ratioAverage
Net debt / EBITDABad
Interest coverGood
Valuation
Fair value vs priceGood
EBIT / EV yieldGood
Profitability
Return on invested capitalAverage
Operating marginAverage
Each check is graded against the company's sector, not a fixed number. Checklist score 67/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $11.6B | $11.6B | $12.1B | $12.8B | $13.6B |
| Operating income | $1.8B | $1.3B | $1.6B | $2.1B | $2.0B |
| Net income | $1.2B | $782M | $957M | $1.3B | $1.1B |
| Operating cash flow | $1.9B | $1.6B | $2.1B | $2.0B | $1.9B |
| Operating margin | 15.5% | 11.5% | 13.2% | 16.3% | 15.0% |
| Free cash flow | $1.3B | $961M | $1.5B | $1.5B | $1.3B |
| Diluted EPS | $8.90 | $5.85 | $7.42 | $10.73 | $9.84 |
Fiscal years, from SEC filings.
Technical summary
Daily
Bullish
11 bullish · 1 neutral · 4 bearish
Weekly
Bullish
8 bullish · 1 neutral · 3 bearish
Monthly
Strongly bullish
7 bullish · 1 neutral · 0 bearish
Moving averages (daily)
| SMA 10 | 181.3 | Bullish |
| EMA 10 | 182.6 | Bullish |
| SMA 20 | 179.9 | Bullish |
| EMA 20 | 181.7 | Bullish |
| SMA 50 | 180.5 | Bullish |
| EMA 50 | 185.6 | Bullish |
| SMA 100 | 199.1 | Bearish |
| EMA 100 | 186.6 | Bullish |
| SMA 200 | 173.4 | Bullish |
| EMA 200 | 177.1 | Bullish |
Oscillators (daily)
| RSI (14) | 57.64 | Neutral |
| MACD (12, 26) | 0.08 | Bullish |
| Momentum (12) | 7.08 | Bullish |
| Stochastic %K (14) | 83.71 | Bearish |
| Williams %R (14) | -16.29 | Bearish |
| CCI (20) | 174.1 | Bearish |
Pivot points (classic, last session)
S3 182.6 | S2 184.5 | S1 185.9 | Pivot 187.9 | R1 189.3 | R2 191.3 | R3 192.7 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
DVA SEC filings
4 Aug 2026
10-QSEC EDGAR
Quarterly report
4 Aug 2026
8-KSEC EDGAR
Results of operations
8 Jun 2026
8-KSEC EDGAR
Entered a material agreement; Shareholder vote results
5 May 2026
10-QSEC EDGAR
Quarterly report
5 May 2026
8-KSEC EDGAR
Results of operations
22 Apr 2026
DEF 14ASEC EDGAR
Proxy statement
11 Feb 2026
10-KSEC EDGAR
Annual report
2 Feb 2026
8-KSEC EDGAR
Results of operations
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.